Powder: -20°C for 3 years | In solvent: -80°C for 1 year
McN3716 is a carnitine palmitoyltransferase I (CPT-1) inhibitor for the study of metabolic diseases.
Pack Size | Availability | Price/USD | Quantity |
---|---|---|---|
1 mg | In stock | $ 350.00 | |
5 mg | In stock | $ 970.00 | |
10 mg | In stock | $ 1,200.00 | |
25 mg | In stock | $ 1,590.00 | |
50 mg | In stock | $ 1,980.00 | |
100 mg | In stock | $ 2,500.00 | |
500 mg | In stock | $ 5,000.00 |
Description | McN3716 is a carnitine palmitoyltransferase I (CPT-1) inhibitor for the study of metabolic diseases. |
In vivo | Significantly reducing the levels of all measured HETE and epoxytrienoic acids (EET), nonenzymatic auto-oxidative metabolites of ARA, by 23% to 44% and 32% to 50% compared with vehicle-injected rats, McN3716 (Methyl palmoxirate, MEP) achieves inhibition of brain mitochondrial β-oxidation. Notably, 15-HETE remains unaffected. McN3716 treatment leads to a significant 34% reduction in the level of 6-keto-PGF1α, a byproduct of PGI2 (prostacyclin). Similarly, the brain level of hydroxyeicosapentaenoic acids, nonenzymatic auto-oxidative metabolites of EPA, is reduced by 35% to 76% upon McN3716 treatment relative to the vehicle[1]. |
Synonyms | NSC359682, Methyl palmoxirate |
Molecular Weight | 298.46 |
Formula | C18H34O3 |
CAS No. | 69207-52-9 |
Powder: -20°C for 3 years | In solvent: -80°C for 1 year
You can also refer to dose conversion for different animals. More
bottom
Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc.
McN3716 69207-52-9 Metabolism CPT Mitochondrial Metabolism NSC 359682 McN 3716 McN-3716 NSC359682 Methyl palmoxirate NSC-359682 inhibitor inhibit